Valmark Advisers Inc. Acquires Shares of 2,365 IDEXX Laboratories, Inc. (IDXX)
Valmark Advisers Inc. acquired a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the fourth quarter, HoldingsChannel.com reports. The institutional investor acquired 2,365 shares of the company’s stock, valued at approximately $370,000.
Several other hedge funds and other institutional investors have also bought and sold shares of IDXX. Zions Bancorporation acquired a new position in IDEXX Laboratories during the third quarter worth $162,000. Benjamin F. Edwards & Company Inc. increased its holdings in IDEXX Laboratories by 1,000.0% during the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 1,100 shares of the company’s stock worth $172,000 after buying an additional 1,000 shares during the last quarter. SignalPoint Asset Management LLC acquired a new position in IDEXX Laboratories during the fourth quarter worth $200,000. Ledyard National Bank increased its holdings in IDEXX Laboratories by 58.9% during the fourth quarter. Ledyard National Bank now owns 1,295 shares of the company’s stock worth $203,000 after buying an additional 480 shares during the last quarter. Finally, BB&T Securities LLC acquired a new position in IDEXX Laboratories during the third quarter worth $213,000. Institutional investors own 86.02% of the company’s stock.
IDEXX Laboratories, Inc. (IDXX) opened at $183.16 on Wednesday. The company has a current ratio of 0.97, a quick ratio of 0.80 and a debt-to-equity ratio of -11.26. IDEXX Laboratories, Inc. has a 52-week low of $141.02 and a 52-week high of $198.73. The company has a market cap of $15,970.00, a price-to-earnings ratio of 55.84, a price-to-earnings-growth ratio of 2.24 and a beta of 0.58.
In related news, Director Bruce L. Claflin acquired 1,000 shares of IDEXX Laboratories stock in a transaction on Wednesday, February 7th. The stock was purchased at an average cost of $179.58 per share, with a total value of $179,580.00. Following the completion of the transaction, the director now directly owns 1,000 shares in the company, valued at approximately $179,580. The purchase was disclosed in a document filed with the SEC, which is available through this link. Also, VP Brian P. Mckeon sold 6,602 shares of IDEXX Laboratories stock in a transaction on Monday, February 5th. The stock was sold at an average price of $181.36, for a total transaction of $1,197,338.72. Following the transaction, the vice president now directly owns 47,040 shares of the company’s stock, valued at $8,531,174.40. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 86,762 shares of company stock valued at $15,202,484. Company insiders own 2.77% of the company’s stock.
A number of equities analysts recently weighed in on IDXX shares. Bank of America boosted their target price on shares of IDEXX Laboratories from $200.00 to $220.00 and gave the stock a “buy” rating in a report on Friday, February 2nd. Zacks Investment Research upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $184.00 target price on the stock in a report on Tuesday, October 24th. Stifel Nicolaus restated a “buy” rating and set a $185.00 target price on shares of IDEXX Laboratories in a report on Tuesday, October 24th. Canaccord Genuity restated a “buy” rating and set a $210.00 target price on shares of IDEXX Laboratories in a report on Monday, January 29th. Finally, BidaskClub upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Tuesday, January 16th. One research analyst has rated the stock with a sell rating, six have given a buy rating and one has given a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $194.00.
IDEXX Laboratories Profile
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.